Results 31 to 40 of about 11,994 (242)

High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study

Antimicrobial Agents and Chemotherapy, 2021
Limited data are available on the most appropriate dosing, efficacy, and safety of micafungin in neonates with invasive candidiasis (IC). This study evaluated plasma levels, efficacy, and safety of micafungin at a dose of 8 mg/kg daily for a mean of 13.3
C. Auriti, B. Goffredo, M. Ronchetti, F. Piersigilli, S. Cairoli, I. Bersani, A. Dotta, P. Bagolan, M. Pai   +8 more
semanticscholar   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin [PDF]

Clinical Pharmacokinetics, 2017
Micafungin is a selective inhibitor of the synthesis of fungal 1,3-β-D-glucan, an essential component of the fungal cell wall. It is available as a powder for infusion only and is registered for the treatment of invasive and esophageal candidiasis in addition to prophylaxis of Candida infections in both adults and children.
Wasmann, R.E., Muilwijk, E.W., Burger, D.M., Verweij, P.E., Knibbe, C.A.J., Bruggemann, R.J.   +5 more
openaire   +5 more sources

A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis.

Clinical Infectious Diseases, 2021
Pathogenesis of neonatal candidiasis (NC) is distinct from systemic candidiasis in adults and older pediatric patients due to the significant incidence of central nervous system (CNS) involvement in neonates.
G. Taormina, R. Gopinath, Jason N Moore, Y. Yasinskaya, P. Colangelo, K. Reynolds, Sumati Nambiar   +6 more
semanticscholar   +1 more source

Micafungin-Induced Cell Wall Damage Stimulates Morphological Changes Consistent with Microcycle Conidiation in Aspergillus nidulans

Journal of Fungi, 2021
Fungal cell wall receptors relay messages about the state of the cell wall to the nucleus through the Cell Wall Integrity Signaling (CWIS) pathway. The ultimate role of the CWIS pathway is to coordinate repair of cell wall damage and to restore normal ...
Samantha Reese, Cynthia Chelius, W. Riekhof, Mark R. Marten, S. Harris   +4 more
semanticscholar   +1 more source

Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center

Antibiotics, 2023
Delays in the treatment of proven invasive fungal disease have been shown to be harmful. However, empiric treatment for all patients at risk of infection has not demonstrated benefit.
J. Myles Keck, David A. Cretella, Kayla R. Stover, Jamie L. Wagner, Katie E. Barber, Tulip A. Jhaveri, Prakhar Vijayvargiya, Zerelda Esquer Garrigos, Mary Joyce B. Wingler   +8 more
doaj   +1 more source

An immunomodulatory activity of micafungin in preclinical aspergillosis [PDF]

Journal of Antimicrobial Chemotherapy, 2013
Micafungin inhibits 1,3-β-D-glucan synthase and interferes with fungal cell wall synthesis. Clinically, micafungin has been shown to be efficacious for the treatment of invasive fungal infections. However, little is known about the immunomodulatory activity of micafungin in these infections.We evaluated the immunomodulatory activity of escalating doses
Silvia Moretti, Silvia Bozza, Cristina Massi-Benedetti, Lucia Prezioso, Elena Rossetti, Luigina Romani, Franco Aversa, Lucia Pitzurra   +7 more
openalex   +6 more sources

Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.

Journal of Antimicrobial Chemotherapy, 2021
OBJECTIVES To determine the pharmacokinetics of twice-a-week micafungin prophylaxis in paediatric leukaemic patients to provide the rationale for this approach.
D. Bury, T. Wolfs, R. ter Heine, E. Muilwijk, W. Tissing, R. Brüggemann   +5 more
semanticscholar   +1 more source

Do Candida albicans Isolates with Borderline Resistant Micafungin MICs Always Harbor FKS1 Hot Spot Mutations?

Journal of Fungi, 2021
Antifungal susceptibility testing is important in guiding patient therapy due to an increasing number of resistant Candida isolates. In the clinical strain collection of the Austrian resistance report (AURES), a high number of micafungin-resistant C ...
Kathrin Spettel, Sonia Galazka, Richard Kriz, I. Camp, B. Willinger   +4 more
semanticscholar   +1 more source

Micafungin Effectiveness in Treating Pediatric Patients with Proven Candidemia

Journal of Pediatric Research, 2022
Aim:Micafungin is one of three currently available echinocandin for the treatment of candidiasis and candidemia. We aimed to discuss the effectiveness of micafungin and any possible side effects in the treatment of proven candidemia in children.Materials
Kamile Ötiken Arıkan, Oğuzhan Kalkanlı, Şebnem Çalkavur, Şeyma Akkuş, Mustafa Çolak, Elif Böncüoğlu, Elif Kıymet, Aybuke Akaslan Kara, Hasan Agın, Nuri Bayram, İlker Devrim   +10 more
doaj   +1 more source

Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections

Antimicrobial Agents and Chemotherapy, 2021
The objective of this study was to describe the pharmacokinetics (PK) of micafungin in plasma and peritoneal fluid in septic patients with intra-abdominal infections.
Nicolas Garbez, L. Mbatchi, S. Wallis, L. Muller, J. Lipman, J. Roberts, J. Lefrant, C. Roger   +7 more
semanticscholar   +1 more source